RU2292888C9 - Применение производных пироиндолона для приготовления противораковых лекарств - Google Patents

Применение производных пироиндолона для приготовления противораковых лекарств Download PDF

Info

Publication number
RU2292888C9
RU2292888C9 RU2003130376/15A RU2003130376A RU2292888C9 RU 2292888 C9 RU2292888 C9 RU 2292888C9 RU 2003130376/15 A RU2003130376/15 A RU 2003130376/15A RU 2003130376 A RU2003130376 A RU 2003130376A RU 2292888 C9 RU2292888 C9 RU 2292888C9
Authority
RU
Russia
Prior art keywords
methyl
group
hydrogen
compounds
pyrido
Prior art date
Application number
RU2003130376/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2292888C2 (ru
RU2003130376A (ru
Inventor
Бернар БУРРЬЕ (FR)
Бернар БУРРЬЕ
Пьер КАЗЕЛЛА (FR)
Пьер Казелла
Жан-Мари ДЕРОК (FR)
Жан-Мари Дерок
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of RU2003130376A publication Critical patent/RU2003130376A/ru
Publication of RU2292888C2 publication Critical patent/RU2292888C2/ru
Application granted granted Critical
Publication of RU2292888C9 publication Critical patent/RU2292888C9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2003130376/15A 2001-04-27 2002-04-26 Применение производных пироиндолона для приготовления противораковых лекарств RU2292888C9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/05,843 2001-04-27
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (3)

Publication Number Publication Date
RU2003130376A RU2003130376A (ru) 2005-04-10
RU2292888C2 RU2292888C2 (ru) 2007-02-10
RU2292888C9 true RU2292888C9 (ru) 2007-06-20

Family

ID=8862882

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003130376/15A RU2292888C9 (ru) 2001-04-27 2002-04-26 Применение производных пироиндолона для приготовления противораковых лекарств

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385512B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2444334A1 (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ295224B6 (enExample)
DE (2) DE60214533T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2271264T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158266A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
FR2765581A1 (fr) * 1997-07-03 1999-01-08 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
RU99101069A (ru) * 1996-06-20 2000-12-10 Клинге Фарма ГмбХ Амиды пиридилалкеновых и пиридилалкиновых кислот в качестве цитостатиков и иммуносупрессорных агентов

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
JPH10501686A (ja) * 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのｄｎａのａａｖ仲介送達
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
RU99101069A (ru) * 1996-06-20 2000-12-10 Клинге Фарма ГмбХ Амиды пиридилалкеновых и пиридилалкиновых кислот в качестве цитостатиков и иммуносупрессорных агентов
FR2765581A1 (fr) * 1997-07-03 1999-01-08 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Харкевич Д.А. Фармакология. - М.: Медицина, 1987, с.47-48. *

Also Published As

Publication number Publication date
CZ20032909A3 (en) 2004-06-16
YU83903A (sh) 2006-08-17
CA2444334A1 (fr) 2002-11-07
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
ES2271264T3 (es) 2007-04-16
WO2002087574A3 (fr) 2003-02-13
EE200300465A (et) 2003-12-15
US20050272760A1 (en) 2005-12-08
IL158266A (en) 2009-09-01
RU2292888C2 (ru) 2007-02-10
NZ528671A (en) 2004-06-25
US7160895B2 (en) 2007-01-09
EA005930B1 (ru) 2005-08-25
NO20034787L (no) 2003-12-23
DE60214533D1 (de) 2006-10-19
EA200301062A1 (ru) 2004-04-29
IL158312A (en) 2009-09-01
PT1385513E (pt) 2007-01-31
CZ295224B6 (cs) 2005-06-15
DE60208365T2 (de) 2006-09-07
YU83403A (sh) 2006-08-17
JP2004531538A (ja) 2004-10-14
AR034313A1 (es) 2004-02-18
SK13242003A3 (sk) 2004-03-02
HK1060066A1 (en) 2004-07-30
IS6984A (is) 2003-10-09
NO20034787D0 (no) 2003-10-24
MXPA03009639A (es) 2004-06-30
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
KR20040015138A (ko) 2004-02-18
DK1385512T3 (da) 2006-05-22
EP1385513B1 (fr) 2006-09-06
DE60214533T2 (de) 2007-06-21
NO20034785L (no) 2003-12-23
CN1505511A (zh) 2004-06-16
DK1385513T3 (da) 2007-01-15
PL366910A1 (en) 2005-02-07
CA2443012C (fr) 2009-07-28
HK1059895A1 (en) 2004-07-23
CZ20032910A3 (en) 2004-07-14
NO20034785D0 (no) 2003-10-24
CZ299465B6 (cs) 2008-08-06
KR100847413B1 (ko) 2008-07-18
CA2443012A1 (en) 2002-11-07
UA74876C2 (en) 2006-02-15
HUP0400745A2 (hu) 2004-08-30
RS50791B (sr) 2010-08-31
EP1385512B1 (fr) 2005-12-28
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
PT1385512E (pt) 2006-05-31
FR2823975A1 (fr) 2002-10-31
RU2003130376A (ru) 2005-04-10
PL366916A1 (en) 2005-02-07
CN1240382C (zh) 2006-02-08
EE200300466A (et) 2003-12-15
ZA200307785B (en) 2004-10-06
BR0209138A (pt) 2004-06-08
US6967203B2 (en) 2005-11-22
US7524857B2 (en) 2009-04-28
JP2004528343A (ja) 2004-09-16
IS2441B (is) 2008-11-15
ATE314070T1 (de) 2006-01-15
IL158312A0 (en) 2004-05-12
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
EP1385513A1 (fr) 2004-02-04
RS50790B (sr) 2010-08-31
SK13252003A3 (sk) 2004-03-02
WO2002087575A1 (fr) 2002-11-07
US20040122027A1 (en) 2004-06-24
CN1505510A (zh) 2004-06-16
US20040122036A1 (en) 2004-06-24
BG108260A (bg) 2004-12-30
CY1105813T1 (el) 2011-02-02
HUP0400744A2 (hu) 2004-06-28
ES2254683T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
US20200071272A1 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
AU687555B2 (en) Medicinal composition as a remedy for non-small cell lung cancer
RU2292888C9 (ru) Применение производных пироиндолона для приготовления противораковых лекарств
CN111821303B (zh) 沃替西汀及其盐在制备抗肿瘤药物中的应用
CN111803489A (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
HK1059895B (en) Use of pyridoindolone derivatives for preparing anticancer medicines
JPH03502806A (ja) ガンの処理
CN120815157A (zh) 多肽化合物在制备治疗和/或减轻肿瘤恶液质的药物中的应用
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
HK1190718A (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Legal Events

Date Code Title Description
TH4A Reissue of patent specification